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The primary objective of this study was to determine the response rates of the gemcitabine and cisplatin combination in unresectable
gall bladder cancer patients. The secondary objectives were to evaluate the toxicity, time to progressive disease, and overall survival.
Chemonaı ¨ve patients with histologically proven, unresectable bidimensionally measurable gall bladder cancer were enrolled into this
study. All patients were required to have a Zubrod’s performance status p2, no prior radiotherapy, and adequate major organ
function. Patients received gemcitabine (1000mgm
 2 intravenously over 30–60min) on days 1 and 8, and cisplatin (70mgm
 2
intravenously over 2h) on day 1, every 21 days. Response assessment was done by a CT scan after every other cycle of
chemotherapy. In all, 30 patients were eligible for efficacy and toxicity analysis. There were four (13.3%) complete responders, seven
(23.3%) partial responders, and seven (23.3%) with stable disease, with four (13.2%) patients showing disease progression. The
median time to progression was 18 weeks (95% confidence interval (CI) 14–24 weeks), and the median duration of response was
13.5 weeks (range 5.5–104 weeks). The median overall survival was 20 weeks (95% CI 14–31 weeks), with 1-year survival rate of
18.6%. WHO grade 3 or 4 anaemia was seen in seven (23.3%) and four (13.3%) patients, respectively. Five (16.6%) patients each
experienced grade 3 or 4 neutropenia, and grade 3 or 4 thrombocytopenia was seen in three (10%) and two (6.6%) patients,
respectively. The present study shows that gemcitabine/cisplatin combination is well tolerated and active in advanced unresectable
gall bladder cancer.
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Adenocarcinoma of the gall bladder and biliary ducts accounts for
approximately 4% of all malignant neoplasms of the gastro-
intestinal tract (Greenlee et al, 2001), and remains a major
challenge to surgical, medical, and radiation oncologists. For a
small percentage of patients who present with resectable disease,
the treatment of choice is surgical resection. However, the general
outcome remains disappointing even in patients undergoing
aggressive surgery (De Groen et al, 1999).
Most patients with gall bladder cancer present with invasive,
inoperable disease. Chemotherapeutic agents including 5-fluor-
ouracil (5FU), mitomycin C, cisplatin, methotrexate, etoposide,
and doxorubicin have been tried alone, and in combination, for
this patient group. Partial responses lasting from weeks to several
months have been observed only in about 10–20% of the cases,
and the median survival for patients with gall bladder cancer is
dismal at around 4 months (Verderame et al, 2000). Chemoim-
munotherapy has shown encouraging results (Murakami et al,
1998; Hasegawa et al, 1999), but the data are limited to a few case
reports only. Similarly, isolated reports of intra-arterial che-
motherapy (Hara et al, 2000) and intralesional therapy (Makower
et al, 2003) have been published. The poor therapeutic results,
along with small sample size in the trials, preclude the support of
any particular chemotherapeutic regimen for unresectable disease.
Therefore, newer, more effective treatment strategies must be
evaluated.
Gemcitabine is a pyrimidine analogue of deoxycytidine and has
shown strong antitumour activity in a variety of solid tumours.
Cisplatin is a stable platinum complex, which is converted into a
reactive electrophile at lower chloride concentrations and binds
covalently to DNA, resulting in apoptosis. Cisplatin has synergistic
activity with gemcitabine (Peters et al, 1995).
Additionally, the gall bladder shares a common embryonic
origin with exocrine pancreas, where gemcitabine has shown
antineoplastic effectiveness (Moore, 1996). These factors
prompted us to plan a phase II trial using a combination of
gemcitabine and cisplatin in the treatment of chemotherapy-naive
patients with unresectable gall bladder cancer. The primary
objective of this study was to determine the response rate. The
secondary objectives were to evaluate the toxicity, time to
progressive disease (PD), and the overall survival for this
combination.
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Eligibility criteria
Chemonaive patients, with histologically proven unresectable
bi-dimensionally measurable gall bladder cancer on a CT scan
or X-ray, were entered into this study. Patients 418 years
of age; Zubrod’s performance status p2; ANC41500mm
 3;
platelets4100000mm
 3;H b 49g%; child-bearing potential ter-
minated by surgery, radiation, menopause, or attenuated by the
use of an approved contraceptive method; and with an estimated
life expectancy of at least 12 weeks were eligible. Patients who had
received prior radiotherapy were eligible, provided that the
irradiated area was not the only source of measurable disease
and the radiation was completed at least 3 weeks prior to
enrolment into the study. Patients were excluded if they were
pregnant or breastfeeding, had a history of previous carcinoma in
the last 5 years, and ALT/AST/transaminases 43 ULN (in case of
liver metastasis ALT/AST 45 ULN). The study was conducted
after obtaining approval from the Ethical Review Board of each
participating institution, as well as written informed consent from
each patient.
Treatment plan
Patients received 1000mgm
 2 of gemcitabine in 100ml saline via
intravenous infusion over 30–60min on days 1 and 8 of a 21-day
cycle, in an outpatient clinic. Cisplatin, 70mgm
 2, diluted in
500ml of 0.9% normal saline, was given intravenously on day 1,
after completing the gemcitabine dose. Cisplatin dose was also
preceded by pre-hydration and electrolyte supplementation as per
institutional practice, or the manufacturer’s recommendation. The
cycle was repeated every 3 weeks for a maximum of six cycles,
unless there was prior evidence of PD.
Drug doses were modified within a cycle based on white
blood cells (WBC), platelet count, and clinical assessment
of nonhaematologic toxicities carried out a day prior to
chemotherapy. If the ANC was between 1000 and 1500mm
 3,
and/or platelet count was between 75000 and 100000mm
 3,
gemcitabine was administered at 75% of the full dose. If the ANC
count was between 500 and 999mm
 3, and/or the platelet count
was between 50000 and 74999mm
 3, gemcitabine was adminis-
tered at 50% of the full dose. Gemcitabine was withheld if the ANC
count was o500mm
 3, and/or the platelet count was
o50000mm
 3. Doses held for toxicity within a cycle were not
to be given at a later time. Prior to starting a new cycle, a value of
ANC41500mm
 3 and platelets4100000mm
 3 was required. In
the event of neutropenia or thrombocytopenia the cycle was
delayed, and CBC was repeated twice weekly until this value was
reached. Prior to start of a new cycle, for serum creatinine levels
between 1.6 and 2mgdl
 1, the cisplatin dose was decreased by
50%, and for levels 42.0mgdl
 1 cisplatin was to be withheld. If
the value was higher than that mentioned above, creatinine was
repeated weekly and the cycle was delayed until the value dropped
to o2mgdl
 1. If cisplatin was held for any length of time (1–4
weeks), re-treatment was done at 50% of the full dose. If the
criteria for re-treatment were not met within 4 weeks, the patient
was to be taken off protocol. Based on the physician’s discretion, a
dose was either reduced or withheld for any nonhaematologic and
nonrenal WHO grade 3 or 4 toxicity (except nausea/vomiting and
alopecia).
Doses held due to toxicity or missed within a cycle were not to
be given at a later time, and any patients who could not receive
drug for 4 weeks were discontinued from the study. Chemotherapy
was to be discontinued for PD, clinical deterioration, at the
patient’s request, due to pregnancy or medical judgment by
treating physician, or for patients who received six cycles of
chemotherapy.
Baseline and treatment assessments
Within 2 weeks prior to starting therapy, patients were assessed
by a detailed medical history, physical examination, chest
X-ray, and CT scan of the abdomen. Prior to every new cycle of
therapy, all patients were assessed with a limited medical
history, physical examination, including weight and performance
status, complete blood count, and renal and hepatic function
tests. CT scan of the abdomen and chest X-ray were done every
other cycle for response assessment. In addition, a complete blood
count was carried out prior to giving the day 8 dose of
gemcitabine.
All patients who received at least one cycle of chemotherapy
with gemcitabine and cisplatin were eligible for efficacy and
toxicity analysis. A complete response (CR) was defined as the
disappearance of all known disease determined by two observa-
tions not less than 3 weeks apart. A PR was defined as at least a
50% decrease in measurable disease by two observations not less
than 3 weeks apart, and no evidence of any new lesions or
progression of any existing lesions. An inability to demonstrate a
50% decrease in tumour size or a 25% increase in the size of one or
more lesions, as well as no new lesions, defined SD. A 25% increase
in the size of one or more measurable lesions, or the appearance of
any new lesions, defined PD.
The duration of response was calculated as the duration
between the first documented response (CR/PR/SD) and PD
or death, whichever is earlier. Survival was measured from
the administration of the first dose until the date of death.
Time to progression was defined as the time of administration
of first dose of chemotherapy to the date of PD or death,
whichever occurred earlier. Toxicity was recorded as per WHO
criteria.
Statistical analysis
The primary end point of this study was response rate. The
width of the resultant confidence intervals (CIs) for parameters
to be estimated were constructed with a significance level
of 0.05, that is, a 95% CI. The Kaplan–Meier survival analysis
method was used to estimate the median survival time for
overall survival, as well as time to progression, and estimates
were provided with 95% CIs. Statistical analysis was performed
using SAS 8.02 (SAS Institute Inc.). Wilcoxon signed rank
test was used to analyse the statistical significance of change in
the grades of ZPS status from cycle 1 to cycle 3, and cycle 1 to cycle
6. Log rank test was used to compare the differences among the
patients grouped based upon relative dose intensity (RDI) with
median RDI as cutoff. Spearman rank correlation was performed
to analyse the correlation between RDI and overall response
for both the drugs. Cox proportional hazard model was used
to analyse the effect of covariates on overall survival. A final
analysis was based on all follow-up information received until
August 2, 2002.
RESULTS
Patient characteristics
From February to August 2000, 30 patients from four different
institutions were enrolled into the study, and all were evaluable for
efficacy and toxicity analysis. The ratio of male to female patients
was 8:22. Patient characteristics are enumerated in Table 1. In all,
22 (73.0%) patients had a Zubrod’s performance status of 1, and 20
(66.6%) patients had metastatic disease. There was no significant
change seen in the Zubrod’s performance status compared from
baseline to cycle 3 (P¼0.62) or cycle 6 (P¼1), as shown in
Figure 1. No grade41 weight loss was observed during therapy
(Figure 2).
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A total of 110 cycles of chemotherapy were administered. Median
number of cycles given was 4.5 (range 1–6). In all, 16 (53%)
patients completed at least four cycles of therapy. The mean
cumulative doses of cisplatin and gemcitabine received were 256
(7154) and 6934 (74510)mg, respectively. The median RDIs of
cisplatin and gemcitabine were 99 and 95%, respectively.
Of the 110 cycles administered in 30 patients, 25 cycles (24%)
were delayed by a mean number of 3.5 days. Only five of these were
delayed due to medical reasons, the remainder was due to social
reasons. The day-8 dose of gemcitabine was omitted in eight cycles
(7%) in six patients, and reduced in six cycles (5%) in five patients,
with a 50% reduction in two cycles and a 75% reduction in four
cycles. Cisplatin dose was reduced in one cycle due to
nephrotoxicity.
Response and time-to-event measures
Four patients achieved a CR (13.3%), seven patients achieved PR
(23.3%), seven patients had SD (23.3%), and four patients showed
PD (13.2%). Response could not be assessed in eight (27%)
patients. Of these eight patients, one withdrew consent, one was
discontinued as per the physician, and three were lost to follow-up.
These three patients failed to turn up after the first cycle of
chemotherapy, and repeated attempts to contact them were not
successful. There were three deaths before evaluation of response,
two of which were thought to be treatment related (septicaemia
and hepatic encephalopathy), and one was due to an unrelated
cause (sudden cardiac arrest). This patient was a known diabetic
for 8 years on irregular treatment, but did not have any known
cardiac disease. In the opinion of the treating investigator (JS
Sekhon), this event was not related to the therapy. The median
TTP was 18 weeks (95% CI; 14–24 weeks; Figure 3). The median
overall survival was 20 weeks (95% CI 14–31 weeks), and 1-year
overall survival was 18.6% (Figure 4). The median duration of
response (CR/PR/SD) was 13.5 weeks (range 5.5–104 weeks). The
median duration of CR in four patients was 58 weeks (range 8–103
weeks). The median duration of PR was 20 weeks (range 15–60
weeks).
The number of chemotherapy cycles given was a significant
prognostic factor affecting overall survival (Table 2). Cox
proportional regression analysis indicates a significant effect of
494% RDI gemcitabine (P¼0.0037), and more than four cycles of
Table 1 Patient characteristics (N¼30)
Sex
Male 8 (27%)
Female 22 (73%)
Median age (range) 53.5 years (21–75)
Zubrod’s performance status
1 22 (73%)
2 8 (27%)
Method of diagnosis
Aspirate 21 (66.6%)
Biopsy 1 (3.3%)
Excision 9 (30%)
Disease status
Metastatic 20 (66.6%)
Recurrent 7 (23.3%)
Locally advanced 3 (10%)
Prior radiation 2 (6.6 %)
73.33 72.73
82.35
75.00
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12.50
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Figure 1 Changes in Zubrod’s performance status across the cycle.
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Figure 3 Kaplan Meier survival analysis for time to PD.
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(Table 3).
Toxicity
The grade 3 and 4 toxicities encountered are listed in Table 4.
There was one episode of febrile neutropenia lasting 4 days. Grade
4 thrombocytopenia requiring transfusion occurred in two
patients. Seven whole blood transfusions were given during the
course of the study. Growth factor support was required in two
patients. There was no episode of bleeding.
DISCUSSION
In this study, we have achieved an RR of 36.6% (95% CI 34–40%)
in 30 evaluable patients, with median response duration of CR/PR
being 58/20 weeks. With an additional 23.3% patients experiencing
stable disease, chemotherapy resulted in abrogation of progression
in 60% of the patients.
Drugs including 5-flourouracil, mitomycin C, cisplatin, metho-
trexate, etoposide, doxorubicin, nitrosoureas, paclitaxel, and
irinotecan have been tested either as single agents or in
combination, without appreciable efficacy in the treatment of
advanced gall bladder cancer. Clinical trials in gall bladder and
hepatobiliary cancers have suffered due to the rarity of occurrence.
The small number of patients in these studies does not allow any
conclusive evidence to be drawn. Carcinomas of the biliary tract
and gall bladder may behave differently with respect to the
biological behaviour and the response to treatment. A prospective
phase III study from Japan has shown a benefit of systemic
chemotherapy in patients with gall bladder cancer undergoing
noncurative resections (Takada et al, 2002). A similar benefit was
not seen in other biliary tract cancers.
Since the commencement of this trial, a number of reports about
the efficacy of chemotherapy in biliary tract cancer have appeared
in the literature. In phase II trials evaluating single-agent activity
of gemcitabine in over 160 patients with advanced biliary tract
cancer, objective RR up to 60% and abrogation of PD
(CRþPRþSD) in 50–93% of patients have been reported
(Metzger et al, 1998; Kubicka et al, 1999; Valencak et al, 1999;
Dobrila et al, 2000; Arroyo et al, 2001; Gebbia et al, 2001; Penz et al,
2001).
Combination chemotherapy of gemcitabine with other agents in
phase II trials involving approximately 130 patients has shown
responses ranging from 9 to 53%, with a tolerable toxicity profile
(Andre et al, 2001; Carraro et al, 2001; Gebbia et al, 2001; Kuhn
et al, 2001; Kornek et al, 2002; Scheithauer, 2002; Murad et al,
2003). Overall survival in these studies ranged from 6.3 to 16
months. Most of these studies have included all biliary tract
cancers. The preliminary results of our study had also confirmed
these findings (Doval et al, 2001, 2002). A recent phase II study
(Malik et al, 2003) using the combination of gemcitabine and
cisplatin in advanced gall bladder cancer has reported high activity
(64% RR) with a tolerable toxicity profile. The encouraging results
of this combination in the present study, along with the reports in
other phase II trials, suggest that gemcitabine may have an active
role in the management of gall bladder cancer. The present data
and literature review, however, do not address the question
whether this combination is superior or equivalent to single-agent
gemcitabine.
Further research in this area should be directed to define the
best cytotoxic agent for combination with gemcitabine, or altering
the dose intensity or route of administration in advanced gall
bladder cancer. A larger trial of gemcitabine alone vs combination
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Figure 4 Kaplan Meier curve for overall survival of patients.
Table 2 Survival analysis for individual covariates
Covariate Stratification
Estimated
median
(weeks)
Test of equality
(P-value for log
rank test)
Age Less than 50 27.857 0.0517
More than 50 19.429
Zubrod’s performance
status
Grade 0,1 27.857 0.0211
Grade 2,3,4 14.429
No of cycles Less than 3 10.429 o0.0001
More than 3 35.643
Sex Male 18.214 0.3857
Female 20.286
Table 3 Cox proportional hazard regression with covariates
Variable Standard error v
2 Pr4v
2 Hazard ratio
Gem RDI 494% 0.54465 8.4341 0.0037 0.206
Age 450 years 0.48050 0.3515 0.5533 1.330
Sex F 0.50615 0.0157 0.9003 0.939
Zubrod’s PS X2 0.66478 0.0893 0.7650 0.820
Cycles 43 0.66587 8.7275 0.0031 0.140
gem¼gemcitabine, Pr¼probability, RDI¼relative dose intensity, PS¼performance
status.
Table 4 WHO grade (G) 3/4 toxicity
N¼30 patients N¼110 cycles
Parameters Grade 3 (%) Grade 4 (%) Grade 3 (%) Grade 4 (%)
Anaemia 7 (23) 4 (13) 12 (11) 5 (4)
Leukopenia 3 (10) 2 (7) 9 (8) 2 (1)
Granulocytopenia 5 (17) 5 (17) 9 (8) 7 (6)
Thrombocytopenia 3 (10) 2 (7) 5 (4) 2 (1)
Hepatic 2 (7) 1 (3) 2 (1) 1 (1)
Renal 1 (3) 1 (3) 1 (1) 1 (1)
Haemorrhage 1 (3) 0 1 (1) 0
Nausea, vomiting 8 (27) 1 (3) 16 (15) 1 (1)
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Also, the role of gemcitabine/cisplatin combination in the adjuvant
setting in suboptimally resected patients should be further
pursued.
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